Mirum Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Mirum Pharmaceuticals has a total shareholder equity of $232.0M and total debt of $307.7M, which brings its debt-to-equity ratio to 132.6%. Its total assets and total liabilities are $667.9M and $435.9M respectively.
Key information
132.6%
Debt to equity ratio
US$307.67m
Debt
| Interest coverage ratio | n/a |
| Cash | US$284.45m |
| Equity | US$232.02m |
| Total liabilities | US$435.87m |
| Total assets | US$667.89m |
Recent financial health updates
Recent updates
Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results
Nov 15
Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt?
Nov 03Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish
Oct 04Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition
Jul 17Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Fly 46% But Investors Aren't Buying For Growth
Jul 13Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry
May 28Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
Apr 22Mirum Pharmaceuticals: Advancing On Several Key Fronts
Mar 05There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price
Dec 26What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You
Jun 10Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts
Apr 18Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU
Oct 14Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth
Aug 17Mirum Pharmaceuticals announces $80M stock offering
Aug 09Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent
May 27Financial Position Analysis
Short Term Liabilities: MIRM's short term assets ($386.6M) exceed its short term liabilities ($115.8M).
Long Term Liabilities: MIRM's short term assets ($386.6M) exceed its long term liabilities ($320.1M).
Debt to Equity History and Analysis
Debt Level: MIRM's net debt to equity ratio (10%) is considered satisfactory.
Reducing Debt: MIRM's debt to equity ratio has increased from 0% to 132.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MIRM has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MIRM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.